造血干细胞移植后的心血管事件

IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Jacc: Cardiooncology Pub Date : 2023-12-01 DOI:10.1016/j.jaccao.2023.07.007
Alexi Vasbinder PhD, RN , Christopher W. Hoeger MD , Tonimarie Catalan BS , Elizabeth Anderson MPH , Catherine Chu MD , Megan Kotzin BS , Jeffrey Xie MD, PhD , Rayan Kaakati MD , Hanna P. Berlin MD , Husam Shadid MD , Daniel Perry MD , Michael Pan MD , Radhika Takiar MD , Kishan Padalia MD , Jamie Mills MD, PhD , Chelsea Meloche MD , Alina Bardwell BS , Matthew Rochlen , Pennelope Blakely BS , Monika Leja MD , Salim S. Hayek MD
{"title":"造血干细胞移植后的心血管事件","authors":"Alexi Vasbinder PhD, RN ,&nbsp;Christopher W. Hoeger MD ,&nbsp;Tonimarie Catalan BS ,&nbsp;Elizabeth Anderson MPH ,&nbsp;Catherine Chu MD ,&nbsp;Megan Kotzin BS ,&nbsp;Jeffrey Xie MD, PhD ,&nbsp;Rayan Kaakati MD ,&nbsp;Hanna P. Berlin MD ,&nbsp;Husam Shadid MD ,&nbsp;Daniel Perry MD ,&nbsp;Michael Pan MD ,&nbsp;Radhika Takiar MD ,&nbsp;Kishan Padalia MD ,&nbsp;Jamie Mills MD, PhD ,&nbsp;Chelsea Meloche MD ,&nbsp;Alina Bardwell BS ,&nbsp;Matthew Rochlen ,&nbsp;Pennelope Blakely BS ,&nbsp;Monika Leja MD ,&nbsp;Salim S. Hayek MD","doi":"10.1016/j.jaccao.2023.07.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Hematopoietic stem cell transplantation (HSCT) is associated with various cardiovascular (CV) complications.</p></div><div><h3>Objectives</h3><p>We sought to characterize the incidence and risk factors for short-term and long-term CV events in a contemporary cohort of adult HSCT recipients.</p></div><div><h3>Methods</h3><p>We conducted a multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019. Data on demographics, clinical characteristics, conditioning regimen, and CV outcomes were collected through chart review. CV outcomes were a composite of CV death, myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, and sustained ventricular tachycardia and were classified as short-term (≤100 days post-HSCT) or long-term (&gt;100 days post-HSCT).</p></div><div><h3>Results</h3><p>In 3,354 patients (mean age 55 years; 40.9% female; 30.1% Black) followed for a median time of 2.3 years (Q1-Q3: 1.0-5.4 years), the 100-day and 5-year cumulative incidences of CV events were 4.1% and 13.9%, respectively. Atrial fibrillation/flutter was the most common short- and long-term CV event, with a 100-day incidence of 2.6% and a 5-year incidence of 6.8% followed by heart failure (1.1% at 100 days and 5.4% at 5 years). Allogeneic recipients had a higher incidence of long-term CV events compared to autologous recipients (5-year incidence 16.4% vs 12.1%; <em>P =</em> 0.002). Baseline CV comorbidities were associated with a higher risk of long-term CV events.</p></div><div><h3>Conclusions</h3><p>The incidence of short-term CV events in HSCT recipients is relatively low. Long-term events were more common among allogeneic recipients and those with pre-existing CV comorbidities.</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":12.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087323002399/pdfft?md5=60ebc83492bca35efb89a46cd1aa5d7a&pid=1-s2.0-S2666087323002399-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Cardiovascular Events After Hematopoietic Stem Cell Transplant\",\"authors\":\"Alexi Vasbinder PhD, RN ,&nbsp;Christopher W. Hoeger MD ,&nbsp;Tonimarie Catalan BS ,&nbsp;Elizabeth Anderson MPH ,&nbsp;Catherine Chu MD ,&nbsp;Megan Kotzin BS ,&nbsp;Jeffrey Xie MD, PhD ,&nbsp;Rayan Kaakati MD ,&nbsp;Hanna P. Berlin MD ,&nbsp;Husam Shadid MD ,&nbsp;Daniel Perry MD ,&nbsp;Michael Pan MD ,&nbsp;Radhika Takiar MD ,&nbsp;Kishan Padalia MD ,&nbsp;Jamie Mills MD, PhD ,&nbsp;Chelsea Meloche MD ,&nbsp;Alina Bardwell BS ,&nbsp;Matthew Rochlen ,&nbsp;Pennelope Blakely BS ,&nbsp;Monika Leja MD ,&nbsp;Salim S. Hayek MD\",\"doi\":\"10.1016/j.jaccao.2023.07.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Hematopoietic stem cell transplantation (HSCT) is associated with various cardiovascular (CV) complications.</p></div><div><h3>Objectives</h3><p>We sought to characterize the incidence and risk factors for short-term and long-term CV events in a contemporary cohort of adult HSCT recipients.</p></div><div><h3>Methods</h3><p>We conducted a multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019. Data on demographics, clinical characteristics, conditioning regimen, and CV outcomes were collected through chart review. CV outcomes were a composite of CV death, myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, and sustained ventricular tachycardia and were classified as short-term (≤100 days post-HSCT) or long-term (&gt;100 days post-HSCT).</p></div><div><h3>Results</h3><p>In 3,354 patients (mean age 55 years; 40.9% female; 30.1% Black) followed for a median time of 2.3 years (Q1-Q3: 1.0-5.4 years), the 100-day and 5-year cumulative incidences of CV events were 4.1% and 13.9%, respectively. Atrial fibrillation/flutter was the most common short- and long-term CV event, with a 100-day incidence of 2.6% and a 5-year incidence of 6.8% followed by heart failure (1.1% at 100 days and 5.4% at 5 years). Allogeneic recipients had a higher incidence of long-term CV events compared to autologous recipients (5-year incidence 16.4% vs 12.1%; <em>P =</em> 0.002). Baseline CV comorbidities were associated with a higher risk of long-term CV events.</p></div><div><h3>Conclusions</h3><p>The incidence of short-term CV events in HSCT recipients is relatively low. Long-term events were more common among allogeneic recipients and those with pre-existing CV comorbidities.</p></div>\",\"PeriodicalId\":48499,\"journal\":{\"name\":\"Jacc: Cardiooncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":12.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666087323002399/pdfft?md5=60ebc83492bca35efb89a46cd1aa5d7a&pid=1-s2.0-S2666087323002399-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jacc: Cardiooncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666087323002399\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jacc: Cardiooncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666087323002399","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景造血干细胞移植(HSCT)与各种心血管(CV)并发症有关。方法我们对2008年至2019年期间接受自体或异体造血干细胞移植的成年患者进行了一项多中心观察性研究。通过病历审查收集了有关人口统计学、临床特征、调理方案和CV结局的数据。CV结局是CV死亡、心肌梗死、心力衰竭、心房颤动/扑动、中风和持续室性心动过速的综合结果,分为短期(造血干细胞移植后≤100天)或长期(造血干细胞移植后100天)。结果 在3354名患者(平均年龄55岁;40.9%为女性;30.1%为黑人)中,随访时间中位数为2.3年(Q1-Q3:1.0-5.4年),100天和5年的CV事件累计发生率分别为4.1%和13.9%。心房颤动/扑动是最常见的短期和长期心血管事件,百日发病率为2.6%,5年发病率为6.8%,其次是心力衰竭(百日发病率为1.1%,5年发病率为5.4%)。与自体受者相比,异体受者的长期心血管事件发生率更高(5年发生率为16.4% vs 12.1%;P = 0.002)。结论造血干细胞移植受者的短期心血管事件发生率相对较低。结论造血干细胞移植受者的短期心血管事件发生率相对较低,长期事件在异体受者和已有心血管合并症的受者中更为常见。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cardiovascular Events After Hematopoietic Stem Cell Transplant

Background

Hematopoietic stem cell transplantation (HSCT) is associated with various cardiovascular (CV) complications.

Objectives

We sought to characterize the incidence and risk factors for short-term and long-term CV events in a contemporary cohort of adult HSCT recipients.

Methods

We conducted a multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019. Data on demographics, clinical characteristics, conditioning regimen, and CV outcomes were collected through chart review. CV outcomes were a composite of CV death, myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, and sustained ventricular tachycardia and were classified as short-term (≤100 days post-HSCT) or long-term (>100 days post-HSCT).

Results

In 3,354 patients (mean age 55 years; 40.9% female; 30.1% Black) followed for a median time of 2.3 years (Q1-Q3: 1.0-5.4 years), the 100-day and 5-year cumulative incidences of CV events were 4.1% and 13.9%, respectively. Atrial fibrillation/flutter was the most common short- and long-term CV event, with a 100-day incidence of 2.6% and a 5-year incidence of 6.8% followed by heart failure (1.1% at 100 days and 5.4% at 5 years). Allogeneic recipients had a higher incidence of long-term CV events compared to autologous recipients (5-year incidence 16.4% vs 12.1%; P = 0.002). Baseline CV comorbidities were associated with a higher risk of long-term CV events.

Conclusions

The incidence of short-term CV events in HSCT recipients is relatively low. Long-term events were more common among allogeneic recipients and those with pre-existing CV comorbidities.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
12.50
自引率
6.30%
发文量
106
期刊介绍: JACC: CardioOncology is a specialized journal that belongs to the esteemed Journal of the American College of Cardiology (JACC) family. Its purpose is to enhance cardiovascular care for cancer patients by publishing high-quality, innovative scientific research and sharing evidence-based knowledge. The journal aims to revolutionize the field of cardio-oncology and actively involve and educate professionals in both cardiovascular and oncology fields. It covers a wide range of topics including pre-clinical, translational, and clinical research, as well as best practices in cardio-oncology. Key areas of focus include understanding disease mechanisms, utilizing in vitro and in vivo models, exploring novel and traditional therapeutics (across Phase I-IV trials), studying epidemiology, employing precision medicine, and investigating primary and secondary prevention. Amyloidosis, cardiovascular risk factors, heart failure, and vascular disease are some examples of the disease states that are of particular interest to the journal. However, it welcomes research on other relevant conditions as well.
期刊最新文献
Editorial Board Correction Cardiovascular Considerations Before Cancer Therapy Anthracycline Cardiotoxicity in Adult Cancer Patients Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1